UBS (Lux) IS - China A Opportunity (USD) I-A2-acc

Fund Fact Sheet

UBS Equity Funds > UBS Opportunity Equity Funds > UBS (Lux) Investment SICAV - China A Opportunity (USD)

Fund description

• The Fund invests principally in Chinese firms and the majority of net assets are invested in China A Shares, which are stocks in Chinese companies that are registered in China’s local markets and can only be traded by the local Chinese and selected foreign institutional investors who are allotted Qualified Foreign Institutional Investors ("QFII") quota.

• The Fund is managed by a team of experienced equity specialists who are well-acquainted with the Chinese financial markets.

Performance (basis USD, net of fees)¹

![Graph showing performance over time]

1. Fund performance net of fees (left-hand scale)
2. Fund performance per year in % net of fees (right-hand scale)
3. Benchmark (left-hand scale)

Past performance is not a reliable indicator of future results.

1. These figures refer to the past. Source for all data and charts (if not indicated otherwise): UBS Asset Management
2. Reference Index in currency of share class (without costs)

Name changed on 24.11.2016: from UBS (Lux) Institutional SICAV II - China A Opportunity (USD) to UBS (Lux) Investment SICAV - China A Opportunity (USD)

Key Figures

<table>
<thead>
<tr>
<th>2 years</th>
<th>3 years</th>
<th>5 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beta</td>
<td>0.86</td>
<td>n.a.</td>
</tr>
<tr>
<td>Correlation</td>
<td>0.89</td>
<td>n.a.</td>
</tr>
</tbody>
</table>

Volatility²

- Portfolio: 20.55%
- Benchmark: 21.20%

Tracking error (ex post)

- Portfolio: 9.78%
- Benchmark: 11.96%

Information ratio

- Portfolio: 0.98%
- Benchmark: 1.79%

Sharpe ratio

- Portfolio: 1.64%
- Benchmark: 1.79%

Risk free rate

- Portfolio: 0.79%
- Benchmark: 0.79%

R²

- Portfolio: 0.65%
- Benchmark: 0.65%

¹ Annualised standard deviation

For more information

Phone: +352-45-12 11
Internet: www.ubs.com/luxembourgfunds
Contact your client advisor

Portfolio management representatives

Bin Shi
Morris Wu
Denise Cheung

Name of fund
UBS (Lux) Investment SICAV - China A Opportunity (USD)
Share class
UBS (Lux) Investment SICAV - China A Opportunity (USD) I-A2-acc
ISIN
LU1675058645
Bloomberg
UBCIA2A LX

Currency of fund / share class
USD/USD
Launch date
14.06.2018
Ongoing charges p.a.
1.17%
Swing pricing
yes
Accounting year end
31 January
Benchmark
MSCI China A Onshore (net div. reinv.)
Distribution
Reinvestment
Management fee p.a.
0.920%
Flat fee p.a.
1.15%
Minimum investment
–
Name of the Management Company
UBS Fund Management (Luxembourg) S.A., Luxembourg
Fund domicile
Luxembourg

Fund Statistics

<table>
<thead>
<tr>
<th>30.10.2020</th>
<th>30.10.2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net asset value (USD)</td>
<td>140.06</td>
</tr>
<tr>
<td>Last 12 months (USD) – high</td>
<td>95.23</td>
</tr>
<tr>
<td>Total fund assets (USD m)</td>
<td>2 026.15</td>
</tr>
<tr>
<td>Share class assets (USD m)</td>
<td>502.08</td>
</tr>
</tbody>
</table>

For marketing purposes
Luxembourg edition
Data as at end-October 2020
For professional clients / qualified investors only
## Sector exposure (%)

<table>
<thead>
<tr>
<th>Sectors</th>
<th>Portfolio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Financial Services</td>
<td>21.43</td>
</tr>
<tr>
<td>Information Technology</td>
<td>15.72</td>
</tr>
<tr>
<td>Consumer Staples</td>
<td>14.37</td>
</tr>
<tr>
<td>Industrials</td>
<td>12.24</td>
</tr>
<tr>
<td>Health Care</td>
<td>10.87</td>
</tr>
<tr>
<td>Consumer Discretionary</td>
<td>8.93</td>
</tr>
<tr>
<td>Materials</td>
<td>7.96</td>
</tr>
<tr>
<td>Real estate</td>
<td>3.16</td>
</tr>
<tr>
<td>Communication Services</td>
<td>2.24</td>
</tr>
<tr>
<td>Utility</td>
<td>1.70</td>
</tr>
<tr>
<td>Energy</td>
<td>1.20</td>
</tr>
<tr>
<td>Cash</td>
<td>0.18</td>
</tr>
</tbody>
</table>

## 10 largest positions (%)

<table>
<thead>
<tr>
<th>Portfolio</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>WULIANGYE YIBIN CO LTD-A</td>
<td>9.56</td>
</tr>
<tr>
<td>KWEICHOW MOUTAI A CNY1</td>
<td>9.53</td>
</tr>
<tr>
<td>JIANGSU HENGRUI MEDICINE CO A</td>
<td>9.41</td>
</tr>
<tr>
<td>YUNNAN BAIYAO GROUP CO LTD-A</td>
<td>9.22</td>
</tr>
<tr>
<td>TENCENT HOLDINGS LTD</td>
<td>4.88</td>
</tr>
<tr>
<td>GREE ELECTRIC APPLIANCES A</td>
<td>4.86</td>
</tr>
<tr>
<td>MIDEA GROUP CO LTD-A</td>
<td>4.83</td>
</tr>
<tr>
<td>PING AN BANK CO LTD A</td>
<td>4.83</td>
</tr>
<tr>
<td>CHINA MERCHANTS BANK A CNY1</td>
<td>4.75</td>
</tr>
<tr>
<td>ALIBABA GROUP HOLDING LTD</td>
<td>4.67</td>
</tr>
</tbody>
</table>

## Benefits

Easy access to investment opportunities provided by a rapidly growing Chinese economy. Investors gain access to local Chinese shares, e.g. China A shares. An experienced portfolio management team, that can leverage local investment expertise in the Chinese market via our joint venture UBS SDIC in China.

## Risks

UBS Opportunity Equity Funds invest in equities and may therefore be subject to high fluctuations in value. For this reason, an investment horizon of at least five years and corresponding risk tolerance and capacity are required. As these UBS Funds pursue an active management style, each Fund’s performance can deviate substantially from that of its reference index. All investments are subject to market fluctuations. This Fund has specific risks related to Chinese investments, which can significantly increase given the specific market and market regulation.